Reaction
Nail Infection reporting signals
As of the last recalculation, Nail Infection appears in 1,414 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is LAPATINIB (PRR 36.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Lapatinib | 37 | 36.0 | 36.1 |
| Ado-Trastuzumab Emtansine | 18 | 31.8 | 31.9 |
| Chlorhexidine Gluconate | 18 | 29.4 | 29.4 |
| Quinine | 16 | 27.8 | 27.8 |
| Calcium Gluconate | 21 | 26.0 | 26.1 |
| Pertuzumab | 43 | 24.0 | 24.0 |
| Trimethoprim | 16 | 20.2 | 20.2 |
| Exemestane | 28 | 19.6 | 19.6 |
| Terbinafine Hydrochloride | 11 | 18.4 | 18.4 |
| Tranexamic Acid | 11 | 18.3 | 18.4 |
| Nitrofurantoin | 19 | 17.2 | 17.2 |
| Nitrofurantoin (Monohydrate/Macrocrystals) | 19 | 17.0 | 17.0 |
| Risedronate Sodium | 34 | 16.5 | 16.5 |
| Aprepitant | 20 | 16.2 | 16.2 |
| Anastrozole Tablets | 22 | 15.3 | 15.3 |
| Gefitinib | 9 | 14.8 | 14.8 |
| Trastuzumab | 61 | 13.6 | 13.6 |
| Erlotinib | 8 | 12.2 | 12.2 |
| Capecitabine | 71 | 12.0 | 12.0 |
| Erlotinib Hydrochloride | 9 | 10.6 | 10.7 |
| Sennosides 8.6 Mg Tablets | 15 | 10.6 | 10.6 |
| Anastrozole | 26 | 10.6 | 10.6 |
| Cetuximab | 21 | 10.0 | 10.0 |
| Mupirocin | 9 | 9.9 | 9.9 |
| Ibrutinib | 45 | 8.4 | 8.4 |
| Bimekizumab | 12 | 8.4 | 8.4 |
| Osimertinib | 17 | 7.9 | 7.9 |
| Panitumumab | 8 | 7.6 | 7.6 |
| Trametinib | 12 | 7.4 | 7.4 |
| Avapritinib | 6 | 7.3 | 7.3 |
| Desoximetasone | 9 | 7.0 | 7.0 |
| Docetaxel Anhydrous | 28 | 6.2 | 6.2 |
| Docetaxel | 28 | 6.2 | 6.2 |
| Pegfilgrastim | 20 | 3.0 | 3.0 |
| Ixekizumab | 7 | 2.8 | 2.8 |